Quantcast

Posts related to ‘Dendreon’

Food and Drug Administration logo

Dendreon Gets Prostate Cancer Competition for Provenge from Bayer’s Xofigo

Posted: May 15, 2013 at 11:15 am

Dendreon Corp. (NASDAQ: DNDN) has been facing problems getting its Provenge sales for advanced metastatic prostate cancer through to the market. Even a direct to consumer advertising campaign has so ...
Read Full Story »
biotech

Dendreon Shows Poor Provenge Sales, Implosion Risk Rising

Posted: May 9, 2013 at 10:25 am

Dendreon Corp. (NASDAQ: DNDN) just cannot catch a break. Despite having what was supposed to be one of the best late-stage prostate treatments in Provenge, sales just are not coming ...
Read Full Story »
Bull and Bear figures

Today’s Market Winners and Losers

Posted: January 14, 2013 at 10:36 am

The stock market is down Monday, with the Dow Jones Industrial Average down 0.09%, the Nasdaq down 0.57% and the S&P 500 down 0.33%. Today's winners include a smartphone manufacturer ...
Read Full Story »

Today’s Market Winners and Losers

Posted: November 2, 2012 at 11:04 am

The stock market is down Friday, with the Dow Jones Industrial Average down 0.39%, the Nasdaq down 0.24% and the S&P 500 down 0.17%. Today's winners and losers were both ...
Read Full Story »

Another Dendreon Price Target Cut

Posted: July 31, 2012 at 10:55 am

Canaccord Genuity provided 24/7 Wall St. with a research note on its downgrade of Dendreon (NASDAQ: DNDN): DNDN Target Cut Following Dendreon’s (DNDN) Q2 2012 results Canaccord Genuity biotechnology analyst ...
Read Full Story »

Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)

Posted: May 10, 2012 at 12:02 pm

It is now getting close to the middle of May, and that means one thing for biotech investors.  The king of biotech and pharma events is about to take place.  ...
Read Full Story »

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Posted: April 18, 2012 at 8:23 am

Biotech is a sector which is often mixed with a hodge-podge of winners and losers based on news flow from analysts and/or key drug developments which often have very little to ...
Read Full Story »

Another Bump Up for Dendreon and PROVENGE (DNDN)

Posted: November 21, 2011 at 8:38 am

Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE.  Dendreon noted ...
Read Full Story »

Picking Apart the Dendreon Implosion (DNDN)

Posted: August 4, 2011 at 7:59 am

Dendreon Corporation (NASDAQ: DNDN) was supposed to be the Holy Grail when it comes to investing in a treatment for prostate cancer.  The limited life-extension versus a high cost for ...
Read Full Story »

BioWatch: Dendreon Looks Even Brighter (DNDN)

Posted: April 1, 2011 at 12:17 pm

Earlier this week, we highlighted Dendreon Corporation (NASDAQ: DNDN) as one of five biotechs with 50% implied upside.  A new report is out from Canaccord Genuity that has figures which ...
Read Full Story »

BioWatch: Biotechs With 50% Implied Upside (GENZ, CEPH, ALNY, DNDN, GERN, HALO, VVUS)

Posted: March 30, 2011 at 10:48 am

Biotech is about to become even less of a diversified sector due to mergers and acquisitions. Genzyme Corporation (NASDAQ: GENZ) and Cephalon Inc. (NASDAQ: CEPH) will end up accounting for ...
Read Full Story »